Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Nervous System Firm Eliem Therapeutics Files For $80M IPO

Eliem Therapeutics (NASDAQ: ELYM), a Phase 2a biotech developing therapies for neuronal excitability disorders, filed an IPO prospectus with the SEC to raise up to $80 million. Its two lead candidates are ETX-810 and ETX-155.
byVandana Singh
July 19, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Eliem Therapeutics (NASDAQ:ELYM), a Phase 2a biotech developing therapies for neuronal excitability disorders, filed an IPO prospectus with the SEC to raise up to $80 million.
  • Its two lead candidates are ETX-810 and ETX-155.
  • ETX-810 is currently in two Phase IIa studies looking at diabetic peripheral neuropathic pain and lumbosacral radicular pain. Data readouts are expected for the first half of 2022.
  • ETX-155 is a GABA-positive allosteric modulator, which the company is calling ETX-155. 
  • Researchers plan to take this program into two Phase IIa studies for major depressive disorder and hormone-related depressive disorders, as well as a Phase Ib trial for epilepsy. Data here are expected in the second half of 2022 and the first half of 2023, respectively.
  • IPO Filing prospectus here.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Afghani Currency Hits New Lows As Taliban’s Takeover Continues: What Investors Need To Know

By Wayne Duggan
Today, 3:23 AM
Afghanistan’s currency fell to its lowest levels in history on Wednesday as the Taliban continues its push to gain complete control of the country. What Happened? The Afghani dropped 4.6% on Tuesday and was trading at as low as 86.0625 per dollar. On Wednesday, the Afghani was trading at 79.9358 per dollar.

SPY